Nurexone Biologic IncOTCQB:NRXBFView on Canadian Exchange
- LAST PRICE0.4992
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.3000/ 25
- Ask / Lots0.6500/ 10
- Open / Previous Close--- / 0.4992
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRXBF |
|---|---|---|
| 12:06 ET | 10000 | 0.5286 |
| 01:04 ET | 1000 | 0.4992 |
Nov 13, 2024
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets, from 4:14PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:14PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 1, 2024
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update, from 4:50PM ET on Friday Nov 01, 2024 by Dow Jones
4:50PM ET on Friday Nov 01, 2024 by Dow Jones
Oct 30, 2024
Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now, from 7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
Oct 29, 2024
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now, from 7:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
Oct 23, 2024
NurExone's Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA, from 2:56AM ET on Wednesday Oct 23, 2024 by Dow Jones
2:56AM ET on Wednesday Oct 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nurexone Biologic Inc | 51.7M | --- | --- |
Company Information
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.
Contact Information
- Headquarters
- 9 Mezada Street, Bsr 3 Tower, 30 FloorBNEI BRAK, Israel 5120109
- Phone
- 416-410-5297
- Fax
- 416-410-5297
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $51.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.8M |
Nurexone Biologic Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.11 |
Book Value | $0.01 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
